The FDA began review of Roche’s multiple sclerosis pill, fenebrutinib, in a process that previously had not been accepted in two major forms. The agency’s decision signals momentum for Roche’s oral BTK approach in MS, even as lingering safety questions remain part of the background. For Roche, the key near-term step is how FDA’s review frames benefit-risk while focusing on safety signals associated with the program. The restart in regulatory engagement also keeps pressure on competing oral MS mechanisms that have been building evidence through trials and real-world use. The development matters because oral MS therapies continue to compete on convenience and tolerability, and FDA’s review posture can shape the likelihood and timing of any future label expansion decisions.